Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
Last Closing Price
January 24, 2018
J.P. Morgan, BofA Merrill Lynch, Goldman Sachs, Cowen & Co.
To view the prospectus for Ultragenyx Pharmaceutical Inc., or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277